1)amoxycillin-clavulanic acid阿莫西林-克拉维酸
1.Determination of concentration of amoxycillin-clavulanic acid in human plasma by HPLC method;人血浆中阿莫西林-克拉维酸浓度的测定
英文短句/例句
1.AIM To evaluate the efficacy and safety of amoxicillin-clavulanic acid consecutive therapy in treating acute community-acquired low respiratory tract infections.目的评价阿莫西林-克拉维酸序贯治疗社区获得性急性下呼吸道感染的临床疗效和安全性。
2.Amoxicillin Sodium and Clavulanate Potassium阿莫西林钠克拉维酸钾
3.Amoxicillin and Clavulanate Potassium阿莫西林克拉维酸钾
4.Impurity Profiling Changes of Amoxicillin/Potassium Clavulanate阿莫西林/克拉维酸钾复方制剂杂质谱的变化
5.Study on in vitro Activities of Amo/Cla Dispersible Tablets against β-Lactamase Producing Bacteria阿莫西林/克拉维酸分散片对产β-内酰胺酶菌的体外抗菌作用
6.The relative bioavailability of AMX and CAV granules formulation was 104±20% and 108±11%, respectively.颗粒剂的相对生物利用度阿莫西林为104±20％，克拉维酸钾为108±11％。
7.Mechanisms of Resistance to Amoxicillin-clavulanate in Escherichia Coli Isolates;大肠埃希菌对阿莫西林/克拉维酸耐药机制的研究
8.Research of the application of correction factor in the determination of amoxicillin and potassium clavulanate tablets校正因子在阿莫西林/克拉维酸钾片含量测定中的应用探讨
9.ticarcillin-clavulnic acid替卡西林-克拉维酸
10.Ticarcillin Sodium and替卡西林钠克拉维酸钾
11.Amoxillin and Dicloxacillin阿莫西林双氯西林钠
12.In Vitro Induction of Resistance to Metronidazole, Clarithromycin, Amoxicillin in Helicobacter Pylori Strains Isolated from Children;儿童感染幽门螺杆菌体外诱导甲硝唑、克拉霉素、阿莫西林耐药的初步研究
13.Determination of Amoxicillin and Ciprofloxacin Hydrochloride Soluble Powder Contents by RP-HPLC;RP-HPLC法测定阿莫西林、盐酸环丙沙星可溶性粉
14.Analysis of Amoxicillin Resulted in the Causes of Anaphylactic Shock阿莫西林导致过敏性休克国内文献分析
15.Efficacy of omeprazole,levofloxacin,amoxicillin for treating Helicobacter pylori infection奥美拉唑、左氧氟沙星、阿莫西林联用根除幽门螺杆菌的疗效观察
16.Effect of pantoprazole,amoxicillin and Levofloxacin on peptic ulcer潘托拉唑、阿莫西林和左氧氟沙星联合治疗消化性溃疡的疗效观察
17.The method could be used to control the quality of amoxicillin& ciprofloxacin hydrochloride soluble( powder.本法可用于阿莫西林—盐酸环丙沙星可溶性粉的质量控制。
18.Study on the amoxillin-tylosin tartrate compound against Streptococcos suis in mice阿莫西林钠-酒石酸泰乐菌素复方药物治疗猪链球菌病的研究
相关短句/例句
Amoxicillin and clavulanate potassium阿莫西林克拉维酸钾
1.Study on formulation,preparation and dissolution of amoxicillin and clavulanate potassium(7∶1) tablets;阿莫西林克拉维酸钾(7∶1)片处方、工艺研究及溶出度考察
3)Amoxicillin/clavulanate potassium阿莫西林/克拉维酸钾
1.Intravenous Drip Combined with Oral Administration Versus Sequential Therapy of Amoxicillin/Clavulanate Potassium for Lower Respiratory Tract Infection;阿莫西林/克拉维酸钾静滴伴口服疗法与序贯疗法治疗下呼吸道感染的疗效比较
2.Antibiotic susceptibility tests and determination of minimal inhibitory concentration(MIC) of amoxicillin/clavulanate potassium were performed.目的了解本地区结核分枝杆菌耐药状况,为选择有效抗生素、特别新药阿莫西林/克拉维酸钾敏感性提供有效数据。
4)amoxicillin-potassium clavulanate阿莫西林/克拉维酸钾
1.The evaluation on the therapeutic efficacy and safety of amoxicillin-potassium clavulanate in treating in-patients with acute exacerbation of chronic obstructed pulmonary disease;阿莫西林/克拉维酸钾对慢性阻塞性肺疾病急性加重期住院治疗患者的疗效及安全性评价
5)Amoxicillin/clavulanate阿莫西林/克拉维酸
1.0 g every 8 hours (serious) compared with amoxicillin/clavulanate in 1.0 g,每12 h或8 h 1次,与阿莫西林/克拉维酸轻度感染每次1。
2.Objectives: To study the resistant mechanisms of amoxicillin/clavulanate -resistant Escherichia coli isolated from West China Hospital of Sichuan University.目的：了解四川大学华西医院大肠埃希菌对阿莫西林/克拉维酸的耐药情况；了解大肠埃希菌对阿莫西林/克拉维酸产生耐药的分子机制；了解TEM、SHY、OXA型广谱酶以及质粒介导的AmpC酶在耐药菌株中的分布；明确整合子在耐药菌株中的分布以及介导耐药基因盒类型；探讨大肠埃希菌对阿莫西林/克拉维酸的耐药特点和机制，从而为临床合理用药及减少耐药的发生和耐药基因传播提供实验研究依据。
6)amoxicillin-clavulante阿莫西林-克拉维酸钾片
1.Meth-ods:20 acute urinary system infected patients were randomly divided into two groups: group A(n = 10), in which the patients were treated with cefetamet pivoxil(250mg, po, bid, pc) for 7 days, and group B(n = 10), in which the patients were administrated with amoxicillin-clavulante (375mg, po, tid, pc) for7days.方法:20例急性泌尿系统感染患者随机分为两组,分别使用头孢他美酯和阿莫西林-克拉维酸钾片(奥格门,Augmemtin)治疗。
延伸阅读
阿莫西林-克拉维酸阿莫西林-克拉维酸 别名：羟氨苄青霉素-棒酸，安美汀(augmentin)。本品系羟氨苄青霉素与棒酸的混合制剂。两者可产生明显的协同作用。克拉维酸可使细菌的β-内酰胺酶失活，恢复细菌对阿莫西林的敏感性。对革兰阳性菌、革兰阴性菌、厌氧菌包括链球菌、肺炎链球菌、炭疽杆菌、化脓链球菌、草绿色链球菌、金黄色葡萄球菌、棒状杆菌、产单核细胞李斯特菌、厌氧芽胞杆菌属、消化球菌及淋病奈瑟菌等均有抗菌活性。本品在胃酸中稳定，口服吸收良好，口服后1～2小时达血药峰值，口服375mg阿莫西林-克拉维酸后，血药阿莫西林峰浓度为4.4μg/ml，蛋白结合率低，50%～70%的阿莫西林经肾排泄。阿莫西林的t1/2为1.3小时，克拉维酸的t1/2为1小时。用于治疗敏感菌引起的尿路、皮肤、呼吸道感染及和女性生殖器官感染。成人：静脉注射或静脉滴注：1.2g/次，3～4次/d。口服：1～2片/次，3次/d。不良反应：①出现肝功能变化，严重肝功能不全患者慎用；②恶心、呕吐、消化不良、伪膜结肠炎、腹泻等；③静注或静脉滴注应缓慢，有时可发生静脉炎；④偶见荨麻疹及麻疹样红疹，严重时可伴有传染性单核细胞增多症。一旦发生应立即停药；⑤本品属FDA妊娠B类药物。
